Dublin, Jan. 2, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/wv...ids_market ) has announced the addition of the "Opioids Market Overview to 2023 - Opioids in Western Europe" report to their offering.
The report provides an estimation of 2013 opioid revenues and forecast consumption and revenues until 2023 in the five major Western European countries: the UK, Germany, France, Italy and Spain. The estimated revenues for 2013 are highest in the UK, which held a share of 52%, followed by Germany with 20%. Spain had the lowest in terms of both consumption (3.3%) and revenues (2.2%).
Their use for medicinal purposes has been highly controversial for several decades. Although recognized as potent painkillers, potential for misuse is high. As a result, all regulatory authorities strive to maintain a fine balance between enforcing strict regulations that will crack down on illicit usage but at the same time ensure accessibility for genuine medical purposes. Amidst concerns regarding inadequate pain management due to low accessibility, there are also concerns regarding a lack of significant clinical evidence of their role in managing chronic pain. However, new abuse-deterrent technologies provide an incentive to prescribe more opioids in pain management by alleviating concerns over misuse potential. The approval of such new drugs and formulations has proved a new impetus to growth in opioid usage in the five major Western European countries.
Opioids are largely used for two medicinal purposes: pain management and substitution treatment for drug dependence. Several of the recently approved and pipeline opioid analgesics have a strong focus on reducing misuse potential, which is one of the most significant barriers to usage in pain management. However, usage is on the rise following the introduction of new abuse-deterrent formulations of fentanyl and oxycodone, and initiatives that aim to rationalize usage in pain management. Demand is also high in substitution treatment. While both methadone and buprenorphine are approved for substitute treatment, buprenorphine usage increased in Europe after the approval of Suboxone in 2006, in combination with naloxone, a pure opioid antagonist that acts as an abuse-deterrent.
The report covers the five major Western European countries (the UK, Germany, France, Italy and Spain) and includes -
An overview of opioids in pain management and substitution treatment, and usage constraints for both
Brief analysis of recent approvals of key abuse-deterrent drugs and their impact on consumption and market growth
Country snapshots, comprising key regulations, consumption, market revenues, market forecasts and key drivers and barriers
An overview of new abuse-deterrent technologies and profiles of key pipeline products
Key Reasons to Purchase:
- Gain a perspective of the opioids market size and key drivers and challenges that dictate the market trends in each of the five major countries in Western Europe
- Gauge the impact of key recently approved abuse-deterrent technologies on opioid usage
- Develop an understanding of how the regulatory landscape affects market potential and growth in each country
- Identify the key molecules that are currently the leading players in each region and those that hold the highest potential in the forecast period
- Scan the pipeline for innovative products with abuse-deterrent technologies that could have an impact on opioid usage in the pain management market
Key Topics Covered:
Executive summary
Opioids: an overview
Drug misuse in Western Europe
Unmet need in pain management
Regulatory landscape
Opioids market in Europe
Country snapshots (UK, Germany, France, Italy, Spain)
Market developments
Appendix
For more information visit http://www.researchandmarkets.com/research/wv...ids_market
Research and Markets Laura Wood, Senior Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals
